The drug "Fermatron" is used in the form of injections. The introduction is carried out in the synovial space of the joints with osteochondrosis. This visco-elastic drug is a one percent solution of the sodium salt of hyaluronic acid (hyaluronan). Means "Fermatron" is a prosthesis (analog) of synovial fluid.
The medicine is intended to replenish synovia gilauronan after damage by traumatic or degenerative disorders in the joint. The mechanism of action of the drug is based on the physicochemical properties and biocompatibility of the drug.
Means "Fermatron" (the instruction contains such information) absorbs direct loads on the joint, and with lateral loads, the drug acts as a lubricant (lubricant). The medicine has a stimulating effect on the cells of synovia, and also protects the cartilage, preventing the penetration of molecules and cells that destroy it.
Means "Fermatron" affects the cause of arthrosis. The medication restores the protective and visco-elastic properties of the fluid in the joints, reduces inflammation, helps restore homeostasis in the cartilage, and also stimulates the synthesis of natural hyaluronan. The medicine effectively eliminates stiffness and pain in the knee and other large synovial joints.
A stable result is noted after the fourth injection of the medication. Persistent therapeutic effect lasts for six months or more from the last injection.
The medication is made ready for administration. The product is released in a disposable syringe equipped with a rubber cap, as well as a thread. This provides a more tight connection with the needle coupling and eliminates the leakage of the drug when introduced into the joint cavity. The use of the drug in this form prevents re-infection with intraarticular injection.
In a series of clinical studies of mutagenic, allergic and toxic effects of the drug was not identified.
Given the properties, the medicine "Fermatron" instruction recommends using to eliminate stiffness or pain in the knee and other joints against the background of traumatic or degenerative changes. The tool is indicated for various stages of osteoarthritis, as well as after arthroscopic manipulations.
The injection regimen of the Fermatron medication is recommended by the instruction to be set individually in accordance with the severity of traumatic or degenerative changes.
The drug is injected into the synovial space in the diseased joint. The interval between injections is usually a week. Intra-articular administration should be carried out by a specialist. Before injection, the injection site is treated with an antiseptic. Exudate (if any) is removed before administration.
The recommended dosage for one injection is two milligrams. For the appearance of a lasting effect, it is necessary, as a rule, four injections (per injection per week), however, in clinical practice, the result is noted after the third injection. Do not use more than five injections per course.
Means "Fermatron-Plus" instruction recommends using 1-3 injections. Duration of use is 1-3 weeks.
Means "Fermatron" instruction does not allow for use in the presence of infected wounds, skin disease, abrasions at the injection site. The drug is not recommended for acute synovitis, with hypersensitivity. Do not prescribe the drug in childhood.
There is no information on the safety of using the drug during lactation and pregnancy. Therefore, the use of the medication is allowed only on the recommendation of a doctor.